- Home
- GBLI vs RCKT Comparison
GBLI vs RCKT Comparison
Compare GBLI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | RCKT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.4M | 534.2M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | GBLI | RCKT |
|---|---|---|
| Price | $28.58 | $3.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 2.3K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $450,098,000.00 | N/A |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | $64.28 |
| P/E Ratio | $16.26 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $25.88 | $2.19 |
| 52 Week High | $34.00 | $8.26 |
Technical Indicators
Market Signals| Indicator | GBLI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 49.23 |
| Support Level | $28.50 | $2.99 |
| Resistance Level | $28.81 | $4.08 |
| Average True Range (ATR) | 0.36 | 0.28 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 100.00 | 38.43 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.